Search Clinical Trials in the European Union

Duration
6-10 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
441-460 of 604 trials

Nevoid Basal Cell Carcinoma Syndrome: Sonidegib Treatment Study

We are studying the effects of Sonidegib on patients with Nevoid Basal Cell Carcinoma Syndrome and sporadic basal cell carcinoma. The trial will assess treatment effectiveness, safety, and quality of life improvements.

Nevoid Basal Cell Carcinoma Syndrome6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Post-Surgical Hypoparathyroidism: Indapamide Treatment

We are studying whether daily Indapamide can help manage calcium levels in patients with post-surgical hypoparathyroidism. This trial will also look at the safety of the treatment and its effects on urinary calcium excretion.

Hypoparathyroidism≤3 monthsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementEndocrinologyInternal Medicine

Huntington's Disease: Innovative Biomarker Study

We are exploring new imaging and cognitive markers to better understand how Huntington's disease progresses. This study aims to identify effective ways to track the disease from early stages.

Huntington's DiseaseConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyPsychiatry

Prostate Cancer Imaging: 99mTc-MIP-1404 SPECT/CT Study

We are comparing a new imaging technique to standard methods for detecting prostate cancer spread in patients. This study aims to see if the new method improves detection of lymph node and bone metastases.

Prostate Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesOtolaryngologyUrology

Pulmonary Tuberculosis: Cysteamine Therapy Study

We are investigating the safety of cysteamine as an additional treatment for adults with pulmonary tuberculosis. This study aims to see how it affects bacterial load and immune response during standard TB therapy.

Pulmonary Tuberculosis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

Preventing Relapses in Minimal Change Nephrotic Syndrome with Rituximab

We are studying whether Rituximab can help adults with Minimal Change Nephrotic Syndrome stay in remission after their first episode. This trial looks at the effectiveness and safety of the treatment over time.

Minimal Change Nephrotic Syndrome1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesNephrology

Advanced Breast Cancer: Inavolisib Treatment Study

We are studying a new treatment combining inavolisib with standard medications for patients with advanced hormone receptor-positive breast cancer. The goal is to see if this combination works better than a placebo in managing the disease.

Advanced Breast Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteOncology

Immune Thrombocytopenia: Rituximab with Belimumab

We are studying whether adding belimumab to rituximab helps adults with persistent immune thrombocytopenia. This trial will compare the effects of the combination treatment to rituximab alone.

Immune Thrombocytopenia>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesHematology

Colorectal Cancer: Dendritic Cell Vaccine Study

We are testing a personalized vaccine made from patients' own cells after surgery for stage IV colorectal cancer. The goal is to see if it safely boosts the immune response against cancer.

Stage IV Colorectal Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Caspofungin for ICU Yeast Infections

We are studying whether caspofungin can help patients in the ICU with yeast infections in the abdomen. The trial compares this treatment to a placebo to see if it improves recovery and reduces mortality.

Yeast Intra-Abdominal Infection (Peritonitis)>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesInfectious DiseasesInternal Medicine

Liver Cirrhosis: RTX001 Macrophage Therapy

We are studying a new treatment using RTX001 autologous macrophages for people with decompensated liver cirrhosis. The trial aims to evaluate its safety and effectiveness in improving liver function.

Liver Cirrhosis>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHepatologyInternal Medicine

HER2 Positive Esophageal Cancer: HERES Trial

We are studying whether adding trastuzumab to standard chemotherapy and immunotherapy helps patients with HER2 positive esophageal squamous cell carcinoma live longer without disease progression.

Esophageal Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Type 3 Spinal Muscular Atrophy: NMD670 Study

We are testing the safety and effectiveness of NMD670 in adults with Type 3 spinal muscular atrophy. The study aims to see if it improves muscle strength and function compared to a placebo.

Spinal Muscular Atrophy Type III3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementNeurologyOrthopedics and Traumatology

Non-Small Cell Lung Cancer: Chemotherapy Plus Osimertinib Study

We are evaluating if adding osimertinib to standard chemotherapy helps patients with advanced non-small cell lung cancer who have progressed after initial osimertinib treatment. This study compares the new treatment approach to chemotherapy with a placebo.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesOncology

TAR-0520 Gel for Folliculitis in Colorectal Cancer Patients

We are testing a new gel to see if it is safe and effective for preventing skin irritation in patients using EGFR inhibitors for colorectal cancer. This study focuses on its use on the face and chest.

Papuloerythematous Drug EruptionEGFR Inhibitor-Induced Folliculitis1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementDermatologyOncology

Pegcetacoplan for Adolescents with Paroxysmal Nocturnal Hemoglobinuria

We are studying the safety and biological activity of pegcetacoplan in patients aged 12-17 with PNH. This trial will help us understand how well the treatment works and its effects on health-related quality of life.

Paroxysmal Nocturnal Hemoglobinuria3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematology

Complicated Urinary Tract Infections in Children: Vabomere Study

We are studying the safety and effectiveness of Vabomere for children aged 3 months to under 12 years with complicated urinary tract infections. This research aims to improve treatment options for these young patients.

Complicated Urinary Tract InfectionAcute Pyelonephritis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesUrology

Heart Health: Treatment for Frequent PVCs

We are studying whether treating asymptomatic patients with frequent PVCs can prevent future heart function problems. This trial compares treatment options to simple monitoring to see which is more effective.

Premature Ventricular Contractions (PVCs)>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Acute Bacterial Skin Infections: IV Oritavancin for Kids

We are studying a single-dose intravenous medication for children with acute bacterial skin infections. The trial aims to assess its safety and how well it works compared to existing treatments.

Acute Bacterial Skin and Skin Structure Infection>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementDermatologyPediatrics

Lyell Syndrome: Mesenchymal Stromal Cells Treatment

We are testing a new treatment using mesenchymal stromal cells for patients with Lyell syndrome. The study aims to see if this treatment can help improve skin healing and overall health.

Lyell Syndrome>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesDermatologyHematology